ArticleAntimicrobial agents and chemotherapy2020
Amlodipine Increases the Therapeutic Potential of Ravuconazole upon Trypanosoma cruzi Infection.
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Lipase-Catalyzed Pathways to the Synthesis of Pharmacologically Active Amides.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Anti-Molecules (Basel, Switzerland) · 2025Article
- Amiodarone and Ravuconazole Combination Potentiates Chemotherapy against Drug-Resistant Trypanosoma cruzi Strains.ACS omega · 2025Article
- Insights into the Antiparasitic Activity of Pyrazole-benzimidazole againstCurrent medicinal chemistry · 2025Article
- Synthesis and Anti-Molecules (Basel, Switzerland) · 2024Article
- Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities.Frontiers in pharmacology · 2023Review
- Combination therapy using nitro compounds improves the efficacy of experimental Chagas disease treatment.Parasitology · 2021Article
- Review on Experimental Treatment Strategies AgainstJournal of experimental pharmacology · 2021Review
- Neurochagas: Experimental and human literature of an uncommon entity (Review).Medicine internationalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mining existing agents that enhance the therapeutic potential of ergosterol biosynthesis inhibitors (EBI) is a promising approach to improve Chagas disease chemotherapy. In this study, we evaluated the effect of ravuconazole, an EBI, combined with amlodipine, a calcium channel blocker, upon
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.